A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 33,675 shares of CCCC stock, worth $81,830. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,675
Previous 37,837 11.0%
Holding current value
$81,830
Previous $215,000 43.72%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$3.6 - $7.0 $14,983 - $29,134
-4,162 Reduced 11.0%
33,675 $121,000
Q3 2024

Nov 14, 2024

BUY
$4.43 - $7.38 $136,638 - $227,628
30,844 Added 441.07%
37,837 $215,000
Q2 2024

Aug 14, 2024

BUY
$4.05 - $8.1 $28,321 - $56,643
6,993 New
6,993 $32,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $119M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.